Please login to the form below

Not currently logged in

GSK driving growth in emerging markets

GlaxoSmithKline has entered into a transformational agreement with South African pharmaceutical company
GlaxoSmithKline (GSK) has entered into a transformational agreement with South African pharmaceutical company, Aspen, as a part of a new strategy to accelerate sales growth in emerging markets and extend its product portfolio.

Under the terms of the agreement with Aspen and its venture partner, Strides Arcolab, GSK will access to a broad portfolio and future pipeline of branded pharmaceutical products on a licence and supply basis across emerging markets.

According to GSK, emerging markets are predicted to grow by 13 per cent - triple the growth rates of Western markets - and will account for 40 per cent of the worldwide pharmaceutical market by 2020. In an attempt to tap into this potential resource, GSK has established a new business model and prioritised investments to boost its geographical footprint in emerging market countries.

"This collaboration gives us access to a renewable, high quality and competitively priced source of branded pharmaceuticals in high demand therapeutic areas," said Andrew Witty, CEO of GSK. "Growth in both population and economic prosperity is leading to increased demand for branded pharmaceutical products."

23rd July 2008


Featured jobs

Subscribe to our email news alerts


Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...